Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
the Kinds of Thailand: Decision in favor of Your Number one Thai Dish! - 2From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- 3Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- 4Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- 5Figure out how to Consolidate a Brain science Certificate with Social Work
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- Top 10 Smash hit Computer games of the Year
- Manual for Financial plan Agreeable PC
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
- Sexual violence part of 'everyday life' in parts of Sudan, charity says
